Tuberculosis News Releases

Mycobacteria Use Protein to Create Diverse Populations, Avoid Drugs
May 31, 2017

Subgroups of tuberculosis (TB)-causing bacteria can persist even when antibiotics wipe out most of the overall population. The need to eliminate these persistent subpopulations is one reason why TB treatment regimens are so lengthy. Now, researchers have shown that a single protein allows mycobacteria to generate diverse populations that can avoid TB drugs. The protein may be a target for intervention; blocking it might result in less mycobacterial diversity and shorten TB treatment courses.

NIH Statement on World Tuberculosis Day
March 24, 2017

Statement of Christine F. Sizemore, PhD., Richard Hafner, M.D., and Anthony S. Fauci, M.D. National Institute of Allergy and Infectious DiseasesNational Institutes of Health

NIH-Supported Scientists Accelerate Immune Response to Tuberculosis in Mice
December 22, 2016

WHAT:New research findings provide insight into the immune system pathways that may be key to developing an effective tuberculosis (TB) vaccine. The study, to be published Thursday in the journal Nature Communications, was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

NIH-Funded Researchers Find Signs TB Can Persist in Lungs Despite Treatment
September 6, 2016

It has been known that the microbe that causes TB, Mycobacterium tuberculosis, can persist in the lungs even after patient tissue samples test negative for the bacteria. In new research appearing in Nature Medicine, intramural researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, together with NIAID grantees, found through the use of positron emission tomography/computerized tomography (PET/CT) scanning that TB lesions can remain in the lungs long after treatment with antibiotics has been completed.

NIH Statement on World Tuberculosis Day
March 23, 2016

On World Tuberculosis (TB) Day 2016, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), reaffirms its commitment to researching ways to better understand, prevent, diagnose and treat TB. March 24 marks the day in 1882 when German microbiologist Robert Koch announced he had discovered Mycobacterium tuberculosis(Mtb), the bacterium that causes TB—an airborne disease that most often attacks the lungs.

Blood Test Can Predict Risk of Developing Tuberculosis
March 23, 2016

One-third of the world’s population is thought to be infected with Mycobacterium tuberculosis (Mtb), the bacterium that causes tuberculosis (TB), but just a small fraction ever develops symptomatic illness.

Experimental Aerosol TB Vaccine Protects Monkeys, NIH-Funded Researchers Find
October 16, 2015

Researchers funded by the National Institute of Allergy and Infectious Diseases have developed an investigational aerosol tuberculosis vaccine that induced potent immune responses in a small number of rhesus macaques and protected them against pulmonary infection with Mycobacterium tuberculosis .

Imaging Techniques Reliably Predict Treatment Outcomes for TB Patients
December 4, 2014

Two medical imaging techniques, called positron emission tomography and computed tomography, could be used in combination as a biomarker to predict the effectiveness of antibiotic drug regimens being tested to treat tuberculosis patients.